YM BioSciences Announces Election of Dr. Kapil Dhingra
News Nov 22, 2012
YM BioSciences Inc. has announced that Kapil Dhingra has been elected by shareholders to the Company's Board of Directors at YM's Annual Meeting of Shareholders held this afternoon.
Dr. Dhingra has 25 years of experience in oncology clinical research and drug development. Previously, Dr. Dhingra held the position of Vice President, Head, Oncology Disease Biology Leadership Team at Roche, playing a key role in the expansion of Roche oncology.
He is currently the Managing Member of KAPital Consulting, a healthcare consulting firm he founded in June 2008 dedicated to assisting biotechnology, pharmaceutical and diagnostic companies realize the full potential of scientific, clinical and commercial advances in oncology.
He serves on the Board of Directors of a number of companies, including Exosome Diagnostics and Algeta.
Throughout his industry career, Dr. Dhingra maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 as Clinical Associate Professor and more recently at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr. Dhingra received his medical training at the All India Institute of Medical Sciences, New Delhi, India.
"As we advance our lead drug CYT387 to the next phase in its development, it is important to continue to strengthen our board with the experience and expertise that Dr. Dhingra brings," said Mr. David Allan, Chairman of YM BioSciences.
Mr. Allan continued, "We would also like to thank Dr. Philip Frost and Dr. François Thomas for their long and valuable participation on the Board of Directors."
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE